Navigation Links
InspireMD Announces the Enrollment of the 1st Patient in the MGuard(TM) Israeli Registry. InspireMD Will Also Sponsor a Satellite Program Breakfast Meeting at the TCT Conference on September 24th 2009 in the Moscone Exhibition Center in San Francisco
Date:9/23/2009

SAN FRANCISCO, September 23 /PRNewswire/ -- InspireMD, developers of MGuard(TM), announced today that the first patient has been enrolled in the Israeli MGuard(TM) Registry. MGuard(TM) was successfully implanted in Natanya, Israel, at the Laniado Hospital Cath Lab, managed by Dr. Yitzhak Herz, the principal investigator for the Registry at this hospital.

The Israeli MGuard Registry will enroll 100 'real world' MGuard patients from eight hospitals in Israel. Data from the registry will be used to support data from other MGuard clinical studies.

The first MGuard Stent in the Israeli MGuard Registry was implanted by Dr. Guy Schoenmann from the Laniado Hospital in Netanya. The patient was a 70 year old male treated for myocardial infarction (MI) caused by a thrombus occluding the right coronary artery. Dr. Schoenmann stated: "MGuard(TM) was delivered with no complications and it immediately enabled excellent flow in the artery. We experienced a very successful procedure and I am very pleased that MGuard is now available to us on daily basis".

Mr. Eli Bar CTO and VP R&D stated: "Currently MGuard is mostly used in AMI, SVG, and thrombus containing lesions. The Israeli MGuard registry is very important for us in order to understand the clinical performance of MGuard in the 'real world' and receive a wider perspective on its use in special patient subgroups".

On September 24th 2009, InspireMD will Sponsor a Breakfast Meeting at the TCT Conference 2009 in San Francisco, Titled "The Role of the MGuard(TM) Stent in Thrombus Management During AMI Interventions". The meeting chairman will be Dr. Martin B. Leon , the Chairman of the CRF, NY; Associate Director at New York Presbyterian Hospital and Professor at Columbia University Medical Center NY. InspireMD's Breakfast Meeting faculty will include Alexandre Abizaid, MD, PhD, Antonio Colombo, MD, Peter J. Fitzgerald, MD, PhD, Jacek Legutko, MD, PhD, Chaim Lotan MD and Christian M. Spaulding, MD, PhD. At the meeting the latest MAGICAL STEMI clinical data will be presented as well as MGuard(TM) in ACS - Data from the Brazilian INSPIRE trial.

About MGuard(TM) Coronary

MGuard(TM) presents a novel combination of a coronary stent merged with an embolic protection. The embolic protection is comprised of an ultra-thin polymer mesh sleeve that wraps the stent. The protective sleeve is composed of a micron-level-fiber which is knit in order to ensure flexibility while retaining the strength characteristics of the fiber material. The sleeve is designed to expand seamlessly when the stent is deployed, without affecting the structural integrity of the stent. The MGuard(TM) coronary stent provides permanent embolic protection, without complicating deliverability. Reduced injury to the vessel as a result of diffused stent pressure is a benefit of the sleeve which may lead to lower risk of restenosis. MGuard(TM) is CE Mark approved.

The MGuard(TM) Coronary's innovative concept has enjoyed an enthusiastic welcome from leading interventional cardiologists around the world.

About InspireMD

InspireMD Ltd. is an innovative medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard(TM). The company intends to apply its technology to develop products used in interventional cardiology and other vascular procedures. InspireMD's mission is to utilize its proprietary technology to make its products the industry standard for stents and to provide a superior solution to the key clinical issues of current stenting: restenosis, embolic showers, and late thrombosis.

In addition to providing embolic protection and minimizing arterial injury, this promising technology can be an effective and uniform drug delivery mechanism with the help of the novel micron-level net for next generation drug eluting stents. InspireMD intends to pursue applications of this technology both for bare metal and drug eluting stents in coronary, carotid and peripheral artery procedures. For further information visit http://www.inspire-md.com

    Contact:

    Jonina Ohayon
    Marketing Director
    Tel +972-52-5791120
    jonina@inspire-md.com



'/>"/>
SOURCE InspireMD
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. InspireMD Announce the Completion of Enrollment for the MAGICAL Trial (MGuard(TM) in Acute Myocardial Infarction) at EuroPCR 09. Results Will be Presented May 21st by Dr. Dariusz Dudek at the InspireMD Cocktail Reception Debate Chaired by Prof. Martin Le
2. MGuard(TM), InspireMDs Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008
3. InspireMD Announces Enrollment of First Patients in the MGuard(TM) Acute Myocardial Infarction Clinical Trial Data Will be Used to Confirm Initial Positive Results
4. MedShape Solutions, Inc. Announces First FDA-cleared Shape Memory PEEK Device; Closing of $10M Equity Offering
5. XRC Medical Imaging Announces Rapid Test Results
6. Volcano Corporation Announces Schedule of Events for the 2009 Transcatheter Cardiovascular Therapeutics (TCT) Conference
7. Boston Scientific Announces Release of Next-Generation iLab(R) System Software
8. Brennen Medical Announces Sale of XenMatrix(R)
9. PROLOR Biotech Announces Initiation of Phase I Clinical Trial for its Long-Acting Growth Hormone
10. AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS-112 in Cancer
11. Halocarbon Announces Licensing Agreement with IBM
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)... Cell Applications, Inc. and StemoniX announced ... up to one billion human induced pluripotent stem ... These high-quality, consistent stem cells enable researchers to ... more time doing meaningful, relevant research. This achievement ... process that produces affordable, reliable HiPSC for life ...
(Date:6/22/2016)... --  StockNewsNow.com , The Official MicroCap News Source™, today ... Pourhassan , President & CEO of CytoDyn Inc. (OTCQB: ... and potential commercialization of humanized monoclonal antibodies for the ... company,s website (see here: www.CytoDyn.com ). The video ... 2016, at the LD Micro Invitational in ...
(Date:6/22/2016)... ... , ... New light-based technologies that facilitate a “look inside” the human body ... compact, wearable devices for point-of-care diagnostics as well as powerful new systems that provide ... visionary future directions are detailed in a new open-access article by Antonio Pifferi and ...
(Date:6/22/2016)... and ALBANY, N.Y. , ... (Teewinot) and Albany Molecular Research, Inc. (NASDAQ: ... licensed Teewinot,s technology to produce and sell the ... The CBCA analytical standard is manufactured using Teewinot,s ... expression of cannabinoid biosynthetic genes in microorganisms for ...
Breaking Biology Technology:
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
(Date:6/2/2016)... , June 2, 2016 The Department ... has awarded the 44 million US Dollar project, for the ... Vehicle Plates including Personalization, Enrolment, and IT Infrastructure , ... in the production and implementation of Identity Management Solutions. Numerous ... however Decatur was selected for the ...
(Date:6/2/2016)... , June 2, 2016 Perimeter ... Platforms, Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... market will generate revenues of $17.98 billion in 2016. ... DVTEL Inc, a leader in software and hardware technologies ...
Breaking Biology News(10 mins):